G Proteins, also known asguanine nucleotide-binding proteins, are a family of membrane resident “go-between” proteins that are important molecular switches in the mediation of GPCR signalling1. In their inactive state, G-proteins exist as heterotrimeric complexes composed of ?, ? and ?-subunits. Upon its stimulation, a GPCR will catalyse the GDPi? GTP exchange at G? leading to the dissociation of the trimer complex as a G?-subunit and the G??-dimer, both able to interact with a number of effector systems responsible for cellular responses. Upon hydrolysis of GTP to GDP+P by G?, the G-protein mediated signalling is terminated, whereby a group of proteins, the regulators of G-protein signalling (RGS) appear to play substantial role1,2.
Every organ system utilises G-protein mediated signal transduction evoking such diverse outcomes as neurotransmission, immunity, cardiovascular function and hormone secretion3. Consequently, GPCRs present a variety of opportunities as therapeutic targets for treating cancer, cardiac dysfunction, central nervous system disorders and pain. In fact, drugs targeting members of this protein superfamily account for 40% of all prescription pharmaceuticals on the market2.
GPCRs constitute the largest and most diversefamily of heptahelical transmembrane receptors that receive a signal (e.g. small peptides, lipid analogues, amino-acid derivatives, and sensory stimuli such as light, taste and odour2)from outside thecelland transmit this signal to the cell interior via interactions with G-proteins leading to activation of downstream effector systems4. In mammals 21 G?-subunits, six G?-subunits and twelve G?-subunits have been described5. Depending on their G? similarity, G-proteins are grouped into four main classes: G?s, G?i/o, G?q/11 and G?12/13 which show selectivity with respect to both, receptors and effectors due to the presence of recognition domains complementary to G-protein binding domains in receptors/effectors6. The main targets for G-proteins include adenylyl cyclase, phospholipase isoforms, Rho A/Rho kinases (a system that controls mainly signalling pathways involved in cell growth/proliferation), and the mitogen activated protein kinase (involved in the control of many cell functions such as cell division), and ion channels7,8.
In its inactivated state the complex is freely diffusible in the plane of the cell membrane due to fatty acid chain anchors on each subunit7. Stimulation of GPCRs by agonists leads to conformational changes in the receptor resulting in the acquirement of high affinity to the G(???) complex. Due to their subsequent association, a GDP->GTP exchange in the ?-subunit will occur leading to dissociation of the G-protein complex from the receptor in form of a G?(GTP)-subunit and a G??-dimer. Prior the activation of the G-protein the G??-dimer is bound to a hydrophobic pocket present in G?-GDP. GTP binding to G? removes the hydrophobic pocket and reduces the affinity of G? for G??9. Both have a signalling function and can interact with various downstream effector systems 7,9. The duration of G protein-mediated effector activation is dependent on the intrinsic GTPase activity of the G?-subunit. GTP-hydrolysis results in dissociation of G?(GDP) from the effector to reunite with G?? completing the cycle7.
Several studies have shown that the kinetics of G-protein signalling are regulated by RGS proteins that can not only act as GTPase activating proteins (GAPs) on G?-subunits hereby accelerating GTP-hydrolysis, but also as scaffolds to help assemble signalling complexes and providing a critical mechanism of regulation of cellular responses10.
Over 30 RGS/RGS-like domain containing proteins have been described and classified into nine distinct subfamilies based on primary sequence homology and presence of additional domains, including the A/RZ (prototype RGSZ), the B/R4 (prototype RGS4), the C/R7 (prototype RGS7), the D/R12 (prototype RGS12), the E/RA (prototype Axin), the F/GEF, G/GRK, H/SNX and I/D-AKAP2 subfamilies3,10,11. They differ widely in their overall size and amino acid identity, and many family members possess a remarkable variety of structural domains and motifs that regulate their actions and/or enable them to interact with other binging partners with diverse cellular roles.
RGS proteins have a highly conserved RGS domain of 120 amino acids3,11 which allows for selective binding to the transition state of G?(GTP->GDP+P)8 , accelerating the GTP-hydrolysis up to a 1000-fold5,10 by stabilising this transition. Some studies have shown that RGS proteins can also act as effector antagonists by binding tightly to G?(GTP), hereby blocking effector activation5,11.
It has been suggested that simple RGS proteins (those of A/RZ and B/R4) have an almost exclusively negative regulatory function acting as modulators of G-protein signalling as for instance shown by the function of RGS4, an effective GAP protein for G?q family members. In mammalian cells RGS4 doesn’t block the receptor and G?q/11-directed inositol lipid/Ca2+ signalling completely but elicit rhythmic Ca2+ oscillations in mammalian cells10, 11. On the contrary, the larger RGS proteins can link active G?s to other signalling pathways and therefore serve as multifunctional integrators. Integration can occur via activation of kinases, recruitment of cellular scaffolds/associated proteins or by direct receptor interactions11. Two of the R12 family members (RGS12 and RGS14) were shown to coordinate components of the Ras/Raf/mitogen-activated protein kinase signalling pathway8,10.
RGS proteins display specificity and selectivity in their interactions not only with G-proteins, but also GCPRs, ion channels and other signalling events3,5 which may be accomplished by firstly, differences in GAP activity towards different types of G?-subunits (e.g. RGS19 was shown to interact strongly with G?i1, G?i3 and G?o, weakly G?i2 but not with G?s and G?q5; secondly, the ability to interact with specific GPCRs or with effectors within the GPCR signalling axis directly, due to presence of characteristic structural domains and motifs (e.g. RGS2 and RGS4 bind selectively the 3rd intracellular loop of M2 and M5 muscarinic receptors5); thirdly, by formation of an RGS/G-protein complex that prevents the G-protein from binding its receptor or the downstream effectors; and lastly, by co-expression of the RGS-proteins with its target protein(s) in order for selective interactions to take place. An example is illustrated by the expression of the alternative spliced RGS9-1 and RGS9-2 in entirely different tissues, thus having different functions and selectivity for different targets. While RGS9-1 is expressed in the photoreceptor cell layers of the retina and is involved in the phototransduction pathway by regulation of photoreceptors, RGS9-2 is predominantly found in the brain and shows selectivity for the regulation of dopamine D2 and opioid µ receptor signalling pathways5.
RGS proteins play and essential regulatory role in G-protein mediated signal transduction, being able to regulate a great number of GCPR signalling events with great specificity and accuracy. By fully understanding the mechanisms and the significance of their expression, role and targets it can lead science to advances in the development of novel therapeutic drugs against disorders involving G-protein mediated signalling.
Baltoumas, F. A., Theodoropoulou, M. C., Hamodrakas, S.J.; Interactions of the a-subunits of heterotrimeric G-proteins with GPCRs, effectors and RGS proteins: A critical review and analysis of interacting surfaces, conformational shifts, structural diversity and electrostatic potentials. Journal of Structural Biology.2013;(182):209-218
Filmore, D.; It’s a GPCR world. Modern Drug Discovery (American Chemical Society).2004; (November): 24–28
Bansal, G., Druey, K.M., Xie, Z.; R4 RGS proteins: regulation of G-protein signaling and beyond. Pharmacology and Therapeutics. 2007;116(3):473-495
Joost, P., Methner, A.; Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool for the prediction of orphan receptor ligands.Genome Biology. 2002;3(11): research0063.1–0063.16
Xie, G.X., Palmer, P.P.; How regulators of G protein signaling achieve selective regulation. Journal of molecular biology. 2007;366(2):349-365
CABRERA-VERA, T.M., VANHAUWE, J., THOMAS, T.O., MEDKOVA, M., PREININGER, A., MAZZONI, M.R., HAMM, H.; Insights into G Protein Structure, Function, and Regulation. Endocrine Reviews. 2003;24(6):765-781
Rang, H.P., Dale, M.M., Ritter, J.M., Flower, R.J., Henderson, G.; Rang and Dale’s Pharmacology. 7th ed. UK. Elsevier Churchill Livingstone ; 2012; 3(32-33)
Kimple, A.J., Bosch, D.E., Giguere, P.M., Siderovski, D.P.; Regulators of G-protein signaling and their G? substrates: promises and challenges in their use as drug discovery targets. Pharmacological Reviews. 2011;63(3):728-749
Oldham, W.M., Hamm, H.; Heterotrimeric G protein activation by G-protein-coupled receptors.NATURE REVIEWS | molecular cell biology. 2008;9:60-71
Keinan, D., Yang, S., Cohen, R.E., Yuan, X., Liu, T., Li, Y.P.; Role of regulator of G protein signaling proteins in bone.Front Biosci (Landmark Ed). 2014;1(19):634-648
Hollinger, S., Hepler, J.R.;. Cellular regulation of RGS proteins: modulators and integrators of G protein signaling.Pharmacological Reviews. 2002;54(3):527-559